Source comparison
BPC-157 ACL Injury Recovery: Mechanism Comparison
BPC-157 (subcutaneous) FAK-paxillin pathway activation + VEGF upregulation +250–300% at 72 hours 40–50% faster migration vs control 30–35% higher at 6 weeks Most comprehensive multi-pathway effect on structural healing. Addresses vascular, inflammatory, and ce
This comparison does not assign a generated winner or score.
- BPC-157 (subcutaneous)
- FAK-paxillin pathway activation + VEGF upregulation
- +250–300% at 72 hours
- 40–50% faster migration vs control
- 30–35% higher at 6 weeks
- Most comprehensive multi-pathway effect on structural healing. Addresses vascular, inflammatory, and cellular adhesion mechanisms simultaneously
- Standard rehab protocol
- Controlled mechanical loading + inflammation resolution
- No direct effect
- Baseline (6–8 weeks lag)
- Baseline collagen architecture
- Relies on endogenous repair capacity. Effective but timeline constrained by natural vascular insufficiency
- NSAID monotherapy
- Cyclooxygenase inhibition (COX-1/COX-2)
- No direct effect; may reduce via inflammation suppression
- Delayed due to macrophage suppression
- 15–20% lower in long-term NSAID use
- Symptom relief without structural benefit. Chronic use associated with weaker tensile strength outcomes
- Platelet-rich plasma (PRP)
- Growth factor delivery (PDGF, TGF-β, IGF-1)
- Transient increase (+40–60%)
- Moderate acceleration
- Variable. Dependent on platelet concentration and preparation method
- Effective for localised growth factor delivery but lacks systemic anti-inflammatory modulation; results inconsistent across studies
- Corticosteroid injection
- Glucocorticoid receptor activation (immune suppression)
- Reduced (−30–50%)
- Suppressed. Delayed fibroblast activity
- Impaired collagen cross-linking
- Potent anti-inflammatory but known to weaken tendon structure long-term; contraindicated in ligament injuries requiring mechanical strength